NO IMPROVEMENT IN SEVERE INFLUENZA OUTCOMES WITH INHALED NITRIC OXIDE THERAPY

Abstract

Severe influenza can lead to significant morbidity and mortality, prompting the exploration of adjunctive therapies such as inhaled nitric oxide (iNO). Nitric oxide has known vasodilatory and anti-inflammatory effects, which theoretically could benefit patients with severe influenza. This study aimed to evaluate the efficacy of iNO therapy in improving outcomes in an experimental model of severe influenza. We conducted a controlled experimental study using [specific animal model or cell line] to simulate severe influenza. Subjects were randomly assigned to receive either inhaled nitric oxide or a placebo. Outcomes measured included survival rates, viral load, lung inflammation, and overall clinical scoring based on disease severity. The administration of inhaled nitric oxide did not lead to a statistically significant improvement in survival rates, reduction in viral load, or amelioration of lung inflammation compared to the placebo group. Clinical scoring of disease severity showed no notable differences between the iNO and control groups. Our findings suggest that inhaled nitric oxide therapy does not confer a beneficial effect on outcomes in experimental severe influenza. Further research may be needed to explore alternative therapeutic approaches or to identify specific patient populations that could potentially benefit from iNO therapy.